112 related articles for article (PubMed ID: 11599800)
41. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients.
Kos J; Stabuc B; Schweiger A; Krasovec M; Cimerman N; Kopitar-Jerala N; Vrhovec I
Clin Cancer Res; 1997 Oct; 3(10):1815-22. PubMed ID: 9815568
[TBL] [Abstract][Full Text] [Related]
42. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
[TBL] [Abstract][Full Text] [Related]
43. Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity.
Lunter PC; van Kilsdonk JW; van Beek H; Cornelissen IM; Bergers M; Willems PH; van Muijen GN; Swart GW
Cancer Res; 2005 Oct; 65(19):8801-8. PubMed ID: 16204050
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma.
Väisänen A; Kallioinen M; Taskinen PJ; Turpeenniemi-Hujanen T
J Pathol; 1998 Sep; 186(1):51-8. PubMed ID: 9875140
[TBL] [Abstract][Full Text] [Related]
45. Serum levels of the soluble adhesion molecules in patients with malignant melanoma.
Yasasever V; Tas F; Duranyildiz D; Camlica H; Kurul S; Dalay N
Pathol Oncol Res; 2000; 6(1):42-5. PubMed ID: 10749587
[TBL] [Abstract][Full Text] [Related]
46. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
47. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation.
Hofmann UB; Eggert AA; Blass K; Bröcker EB; Becker JC
Cancer Res; 2003 Dec; 63(23):8221-5. PubMed ID: 14678978
[TBL] [Abstract][Full Text] [Related]
48. [The serum concentration of metalloproteinase 9 and 2 in non-small cell lung cancer patients].
Kopczyńska E; Dancewicz M; Kowalewski J; Kardymowicz H; Tyrakowski T
Pol Merkur Lekarski; 2007 Jun; 22(132):539-41. PubMed ID: 17874625
[TBL] [Abstract][Full Text] [Related]
49. The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells.
MacDougall JR; Bani MR; Lin Y; Rak J; Kerbel RS
Cancer Res; 1995 Sep; 55(18):4174-81. PubMed ID: 7664294
[TBL] [Abstract][Full Text] [Related]
50. Regulation of MMPs during melanoma progression: from genetic to epigenetic.
Frank A; David V; Aurelie TR; Florent G; William H; Philippe B
Anticancer Agents Med Chem; 2012 Sep; 12(7):773-82. PubMed ID: 22292748
[TBL] [Abstract][Full Text] [Related]
51. Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer.
Dalberg K; Eriksson E; Enberg U; Kjellman M; Bäckdahl M
World J Surg; 2000 Mar; 24(3):334-40. PubMed ID: 10658069
[TBL] [Abstract][Full Text] [Related]
52. [Role of matrix-degrading enzymes in melanoma progression].
Hofmann UB; Becker JC; Bröcker EB
Hautarzt; 2002 Sep; 53(9):587-95. PubMed ID: 12207262
[TBL] [Abstract][Full Text] [Related]
53. Highly invasive melanoma cells activate the vascular endothelium via an MMP-2/integrin αvβ5-induced secretion of VEGF-A.
Desch A; Strozyk EA; Bauer AT; Huck V; Niemeyer V; Wieland T; Schneider SW
Am J Pathol; 2012 Aug; 181(2):693-705. PubMed ID: 22659470
[TBL] [Abstract][Full Text] [Related]
54. Matrix metalloproteinase-12 expression is increased in cutaneous melanoma and associated with tumor aggressiveness.
Zhang Z; Zhu S; Yang Y; Ma X; Guo S
Tumour Biol; 2015 Nov; 36(11):8593-600. PubMed ID: 26040769
[TBL] [Abstract][Full Text] [Related]
55. Serum angiogenin levels predict treatment response in patients with stage IV melanoma.
Vihinen P; Kallioinen M; Vuoristo MS; Ivaska J; Syrjänen KJ; Hahka-Kemppinen M; Kellokumpu-Lehtinen PL; Pyrhönen SO
Clin Exp Metastasis; 2007; 24(7):567-74. PubMed ID: 17762972
[TBL] [Abstract][Full Text] [Related]
56. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
57. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
58. Metalloproteinases in melanoma.
Moro N; Mauch C; Zigrino P
Eur J Cell Biol; 2014; 93(1-2):23-9. PubMed ID: 24530009
[TBL] [Abstract][Full Text] [Related]
59. Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion.
Schnaeker EM; Ossig R; Ludwig T; Dreier R; Oberleithner H; Wilhelmi M; Schneider SW
Cancer Res; 2004 Dec; 64(24):8924-31. PubMed ID: 15604254
[TBL] [Abstract][Full Text] [Related]
60. [Role of matrix metalloproteinases (MMPs) in tumor invasion and metastasis: serial studies on MMPs and TIMPs].
Fang W; Li H; Kong L; Niu G; Gao Q; Zhou K; Zheng J; Wu B
Beijing Da Xue Xue Bao Yi Xue Ban; 2003 Aug; 35(4):441-3. PubMed ID: 12947567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
